Literature DB >> 25634401

Role of "Ischemia Modified Albumin" (IMA) in acute coronary syndromes.

C Bhakthavatsala Reddy1, Cijo Cyriac2, Hrishikesh B Desle3.   

Abstract

BACKGROUND: Diagnosis of acute coronary syndrome (ACS) is important, due to the associated very high mortality. Failure to diagnose ACS is a problem both for the patients and the clinicians. Ischemia modified albumin (IMA) has already been licensed by the US Food and Drug Administration for the diagnosis of suspected myocardial ischemia.
METHODS: Patients attending the emergency department (ED) within 6 h after having features of ACS were selected. IMA was done on admission. Blinded to the IMA results patients were fully evaluated and a diagnosis of non-ischemic chest pain (NICP), unstable angina (UA) or myocardial infarction (MI) was made. Later IMA results were correlated in each group.
RESULTS: Mean IMA value was 56.38 ± 23.89 u/ml in NICP group whereas in UA group it was 89.00 ± 7.76 u/ml and MI group was 87.50 ± 9.62 u/ml. This showed a sensitivity of 92% and specificity of 87%. The positive predictive value of the test was 88% and negative predictive value was 94%. In 16 patients an early diagnosis could be made when compared with Trop-T. Of the 89 patients 11 patients died in hospital. The IMA value was compared between this group and the patients who survived. Patients who died had a mean IMA value of 88.5 with a standard deviation of 5.33 whereas in patients who survived the mean value was 78.26 which was not statistically significant.
CONCLUSION: In conclusion the benefit of the test would be to rule out ACS in patients who present early to ED with inconclusive diagnosis.
Copyright © 2014 Cardiological Society of India. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Acute coronary syndrome; Ischemia modified albumin; Trop T

Mesh:

Substances:

Year:  2014        PMID: 25634401      PMCID: PMC4311005          DOI: 10.1016/j.ihj.2014.12.005

Source DB:  PubMed          Journal:  Indian Heart J        ISSN: 0019-4832


  25 in total

1.  Release characteristics of cardiac biomarkers and ischemia-modified albumin as measured by the albumin cobalt-binding test after a marathon race.

Authors:  Fred S Apple; Heidi E Quist; Angela P Otto; Wendy E Mathews; MaryAnn M Murakami
Journal:  Clin Chem       Date:  2002-07       Impact factor: 8.327

2.  Capability of ischemia-modified albumin to predict serious cardiac outcomes in the short term among patients with potential acute coronary syndrome.

Authors:  Andrew Worster; P J Devereaux; Diane Heels-Ansdell; Gordon H Guyatt; John Opie; Farouk Mookadam; Stephen A Hill
Journal:  CMAJ       Date:  2005-06-21       Impact factor: 8.262

3.  Combinatorial Determination of Ischemia Modified Albumin and Protein Carbonyl in the Diagnosis of NonST-Elevation Myocardial Infarction.

Authors:  Kritsanee Maneewong; Titiporn Mekrungruangwong; Saowanee Luangaram; Tomon Thongsri; Sarawut Kumphune
Journal:  Indian J Clin Biochem       Date:  2011-02-19

4.  The PRIMA study: presentation ischaemia-modified albumin in the emergency department.

Authors:  L Keating; J R Benger; R Beetham; S Bateman; S Veysey; J Kendall; R Pullinger
Journal:  Emerg Med J       Date:  2006-10       Impact factor: 2.740

5.  A novel assay for cobalt-albumin binding and its potential as a marker for myocardial ischemia-a preliminary report.

Authors:  D Bar-Or; E Lau; J V Winkler
Journal:  J Emerg Med       Date:  2000-11       Impact factor: 1.484

6.  Ischemia Modified Albumin for the assessment of patients presenting to the emergency department with acute chest pain but normal or non-diagnostic 12-lead electrocardiograms and negative cardiac troponin T.

Authors:  Debashis Roy; Juan Quiles; Guillermo Aldama; Manas Sinha; Pablo Avanzas; Ramón Arroyo-Espliguero; David Gaze; Paul Collinson; Juan Carlos Kaski
Journal:  Int J Cardiol       Date:  2004-11       Impact factor: 4.164

7.  Ischemia modified albumin: A novel marker for acute coronary syndrome.

Authors:  R Chawla; Navendu Goyal; Rajneesh Calton; Shweta Goyal
Journal:  Indian J Clin Biochem       Date:  2006-03

Review 8.  Ischemia modified albumin: is this marker of ischemia ready for prime time use?

Authors:  Eftihia Sbarouni; Panagiota Georgiadou; Dimitrios Th Kremastinos; Vasilios Voudris
Journal:  Hellenic J Cardiol       Date:  2008 Jul-Aug

9.  Evaluation of human serum albumin cobalt binding assay for the assessment of myocardial ischemia and myocardial infarction.

Authors:  Nadhipuram V Bhagavan; Ernest M Lai; Patricia A Rios; Jinsheng Yang; Anna M Ortega-Lopez; Hiroko Shinoda; Stacey A A Honda; Carlos N Rios; Cheryl E Sugiyama; Chung-Eun Ha
Journal:  Clin Chem       Date:  2003-04       Impact factor: 8.327

Review 10.  Coronary heart disease in Indians: implications of the INTERHEART study.

Authors:  Vamadevan S Ajay; Dorairaj Prabhakaran
Journal:  Indian J Med Res       Date:  2010-11       Impact factor: 2.375

View more
  12 in total

1.  Association between serum lipoprotein-associated phospholipase A2, ischemic modified albumin and acute coronary syndrome: a cross-sectional study.

Authors:  Fumeng Yang; Liping Ma; Lili Zhang; Yilian Wang; Changxin Zhao; Wenjun Zhu; Wei Liang; Qian Liu
Journal:  Heart Vessels       Date:  2019-04-08       Impact factor: 2.037

Review 2.  Novel Invasive and Noninvasive Cardiac-Specific Biomarkers in Obesity and Cardiovascular Diseases.

Authors:  Rajesh Parsanathan; Sushil K Jain
Journal:  Metab Syndr Relat Disord       Date:  2019-10-16       Impact factor: 1.894

3.  Cardiac Biomarkers: What Is and What Can Be.

Authors:  Rachel Jacob; Mahmood Khan
Journal:  Indian J Cardiovasc Dis Women WINCARS       Date:  2018-12

Review 4.  Diagnostic Accuracy of Ischemia-Modified Albumin for Acute Coronary Syndrome: A Systematic Review and Meta-Analysis.

Authors:  Hyungoo Shin; Jae-Guk Kim; Bo-Hyoung Jang; Tae-Ho Lim; Wonhee Kim; Youngsuk Cho; Kyu-Sun Choi; Min-Kyun Na; Chiwon Ahn; Juncheol Lee
Journal:  Medicina (Kaunas)       Date:  2022-04-28       Impact factor: 2.948

5.  Is Ischemia-Modified Albumin a Reliable Marker in Accurate Diagnosis of Appendicitis in Children?

Authors:  Emel Ulusoy; Hale Çitlenbik; Fatma Akgül; Ali Öztürk; Nihan Şık; Oktay Ulusoy; Tuncay Küme; Durgül Yılmaz; Murat Duman
Journal:  World J Surg       Date:  2020-04       Impact factor: 3.352

6.  Study of ischemia modified albumin (IMA) as a biomarker in hypertensive retinopathy.

Authors:  Ecaterina Pavlovschi; Valeriana Pantea; Djina Borovic; Olga Tagadiuc
Journal:  Med Pharm Rep       Date:  2021-04-29

7.  Ischemia modified albumin (IMA) in acute coronary syndrome (ACS) and left bundle branch block (LBBB). Does it make the difference?

Authors:  Mohamed Abdel Kader Abdel Wahab
Journal:  Egypt Heart J       Date:  2017-02-20

8.  Correlation between ischemia-modified albumin level and coronary collateral circulation.

Authors:  Xin Chen; Yan Lin; Lihua Tian; Zhiquan Wang
Journal:  BMC Cardiovasc Disord       Date:  2020-07-08       Impact factor: 2.298

9.  Role of ischemia-modified albumin in patients with acute decompensated heart failure.

Authors:  Defeng Pan; Dongye Li
Journal:  Anatol J Cardiol       Date:  2015-08       Impact factor: 1.596

10.  Plasma Ischemia-Modified Albumin Levels and Dynamic Thiol/Disulfide Balance in Sickle Cell Disease: A Case-Control Study

Authors:  Oğuzhan Özcan; Hüseyin Erdal; Gül İlhan; Damla Demir; Ahmet Burak Gürpınar; Salim Neşelioğlu; Özcan Erel
Journal:  Turk J Haematol       Date:  2018-09-05       Impact factor: 1.831

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.